Top

Published in:

Open Access 01-12-2024 | Lung Cancer | Research

Effects of reprogrammed splenic CD8⁺ T-cells in vitro and in mice with spontaneous metastatic Lewis lung carcinoma

Authors: E. Skurikhin, N. Ermakova, M. Zhukova, E. Pan, D. Widera, L. Sandrikina, L. Kogai, O. Pershina, A. Pakhomova, V. Yu. Pan, N. Kushlinskii, A. Kubatiev, S. Morozov, A. Dygai

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Metastatic disease is a major and difficult-to-treat complication of lung cancer. Considering insufficient effectiveness of existing therapies and taking into account the current problem of lung cancer chemoresistance, it is necessary to continue the development of new treatments.

Methods

Previously, we have demonstrated the antitumor effects of reprogrammed CD8⁺ T-cells (rCD8⁺ T-cells) from the spleen in mice with orthotopic lung carcinoma. Reprogramming was conducted by inhibiting the MAPK/ERK signalling pathway through MEKi and the immune checkpoint PD-1/PD-L1. Concurrently, CD8⁺ T-cells were trained in Lewis lung carcinoma (LLC) cells. We suggested that rCD8⁺ T-cells isolated from the spleen might impede the development of metastatic disease.

Results

The present study has indicated that the reprogramming procedure enhances the survival and cytotoxicity of splenic CD8⁺ T-cells in LLC culture. In an LLC model of spontaneous metastasis, splenic rCD8 + T-cell therapy augmented the numbers of CD8⁺ T-cells and CD4⁺ T-cells in the lungs of mice. These changes can account for the partial reduction of tumors in the lungs and the mitigation of metastatic activity.

Conclusions

Our proposed reprogramming method enhances the antitumor activity of CD8⁺ T-cells isolated from the spleen and could be valuable in formulating an approach to treating metastatic disease in patients with lung cancer.

Available only for authorised users

Dillekås H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019;8:5574–76. https://doi.org/10.1002/cam4.2474.CrossRefPubMedPubMedCentral

Hudock NL, Mani K, Khunsriraksakul C, Walter V, Nekhlyudov L, Wang M, et al. Future trends in incidence and long-term survival of metastatic cancer in the United States. Commun Med (Lond). 2023;3:76. https://doi.org/10.1038/s43856-023-00304-x.CrossRefPubMed

Niu FY, Zhou Q, Yang JJ, Zhong WZ, Chen ZH, Deng W, et al. Distribution and prognosis of uncommon metastases from non-small cell lung cancer. BMC Cancer. 2016;16:149. https://doi.org/10.1186/s12885-016-2169-5.CrossRefPubMedPubMedCentral

Marquardt S, Solanki M, Spitschak A, Vera J, Pützer BM. Emerging functional markers for cancer stem cell-based therapies: understanding signaling networks for targeting metastasis. Semin Cancer Biol. 2018;53:90–109. https://doi.org/10.1016/j.semcancer.2018.06.006.CrossRefPubMed

Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med. 2021;27:34–44. https://doi.org/10.1038/s41591-020-01195-4.CrossRefPubMedPubMedCentral

Raniszewska A, Kwiecień I, Rutkowska E, Rzepecki P, Domagała-Kulawik J. Lung Cancer Stem Cells-Origin, diagnostic techniques and perspective for therapies. Cancers (Basel). 2021;13:2996. https://doi.org/10.3390/cancers13122996.CrossRefPubMed

Turdo A, Veschi V, Gaggianesi M, Chinnici A, Bianca P, Todaro M, et al. Meeting the challenge of Targeting Cancer Stem cells. Front Cell Dev Biol. 2019;7:16. https://doi.org/10.3389/fcell.2019.00016.CrossRefPubMedPubMedCentral

Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M, et al. Immune Checkpoint inhibitors for Lung Cancer treatment: a review. J Clin Med. 2020;9:1362. https://doi.org/10.3390/jcm9051362.CrossRefPubMedPubMedCentral

Chulpanova DS, Rizvanov AA, Solovyeva VV. The role of Cancer Stem cells and their extracellular vesicles in the modulation of the Antitumor immunity. Int J Mol Sci. 2022;24(1):395. https://doi.org/10.3390/ijms24010395.CrossRefPubMedPubMedCentral

10.

Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T cell dysfunction and exhaustion in Cancer. Front Cell Dev Biol. 2020;8:17. https://doi.org/10.3389/fcell.2020.00017.CrossRefPubMedPubMedCentral

11.

Skurikhin EG, Pershina O, Ermakova N, Pakhomova A, Widera D, Zhukova M, et al. Reprogrammed CD8 + T-Lymphocytes isolated from bone Marrow have anticancer potential in Lung Cancer. Biomedicines. 2022;10(6):1450. https://doi.org/10.3390/biomedicines10061450.CrossRefPubMedPubMedCentral

12.

Skurikhin EG, Pershina O, Zhukova M, Pakhomova A, Ermakova N, Widera D, et al. Reprogrammed CD8 + T-Cells isolated from the mouse spleen increase the number of Immune cells with Antitumor activity and decrease the amount of Cancer Stem cells. Med Sci Forum. 2023;21(1):40. https://doi.org/10.3390/ECB2023-14132.CrossRef

13.

Stankevicius V, Kuodyte K, Schveigert D, Bulotiene D, Paulauskas T, Daniunaite K, et al. Gene and miRNA expression profiles of mouse Lewis lung carcinoma LLC1 cells following single or fractionated dose irradiation. Oncol Lett. 2017;13(6):4190–200. https://doi.org/10.3892/ol.2017.5877.CrossRefPubMedPubMedCentral

14.

Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148–54. https://doi.org/10.1007/BF00300234.CrossRefPubMed

15.

Skurikhin EG, Ermakova NN, Pershina OV, Krupin VA, Pakhomova AV, Dygai AM. Response of hematopoietic stem and progenitor cells to Reserpine in C57Bl/6 mice. Bull Exp Biol Med. 2016;160(4):439–43. https://doi.org/10.1007/s10517-016-3191-y.CrossRefPubMed

16.

Skurikhin E, Pershina O, Zhukova M, Widera D, Pan E, Pakhomova A, et al. Spiperone stimulates regeneration in Pulmonary Endothelium damaged by cigarette smoke and Lipopolysaccharide. Int J Chron Obstruct Pulmon Dis. 2021;16:3575–91. https://doi.org/10.2147/COPD.S336410.CrossRefPubMedPubMedCentral

17.

Dunsford LS, Thoirs RH, Rathbone E, Patakas AA, Human. Vitro T cell exhaustion model for assessing Immuno-Oncology therapies. In: Tan SL, editor. Immuno-Oncology. Methods in Pharmacology and Toxicology. New York, NY: Humana; 2020. https://doi.org/10.1007/978-1-0716-0171-6_6.CrossRef

18.

Cardiff RD, Miller CH, Munn RJ. Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc. 2014;2014(6):655–8. https://doi.org/10.1101/pdb.prot073411.CrossRefPubMed

19.

Hather G, Liu R, Bandi S, Mettetal J, Manfredi M, Shyu WC, et al. Growth rate analysis and efficient experimental design for tumor xenograft studies. Cancer Inf. 2014;13(Suppl 4):65–72. https://doi.org/10.4137/CIN.S13974.CrossRef

20.

Tarin D, Price JE. Metastatic colonization potential of primary tumour cells in mice. Br J Cancer. 1979;39(6):740–54. https://doi.org/10.1038/bjc.1979.128.CrossRefPubMedPubMedCentral

21.

Mikuleak NI, Minnigaleeva SD, Magdeyev RR, Kinzirsky AS, Mikulyak AL, Solomanina OO. Valuation of the impact of separate and combined use of carubicinum with probucol, mexidol and Ė-tocopherolon the growth of primary tumor and metastasis oflewis lung carcinoma. Fundamental Res. 2014;7– 4:753– 58.

22.

Chapman HA. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol. 2011;73:413–35. https://doi.org/10.1146/annurev-physiol-012110-142225.CrossRefPubMed

23.

Sukumar M, Liu J, Mehta GU, Patel SJ, Roychoudhuri R, Crompton JG, et al. Mitochondrial membrane potential identifies cells with enhanced stemness for Cellular Therapy. Cell Metab. 2016;23(1):63–76.CrossRefPubMed

24.

Yue X. Epithelial deletion of Sulf2 exacerbates Bleomycin-Induced Lung Injury, inflammation, and Mortality. Am J Respir Cell Mol Biol. 2017;57(5):560–9. https://doi.org/10.1165/rcmb.2016-0367OC.CrossRefPubMedPubMedCentral

25.

Hasegawa K, Sato A, Tanimura K, Uemasu K, Hamakawa Y, Fuseya Y, et al. Fraction of MHCII and EpCAM expression characterizes distal lung epithelial cells for alveolar type 2 cell isolation. Respir Res. 2017;18(1):150. https://doi.org/10.1186/s12931-017-0635-5.CrossRefPubMedPubMedCentral

26.

Donati Y, Blaskovic S, Ruchonnet-Métrailler I, Lascano Maillard J, Barazzone-Argiroffo C. Simultaneous isolation of endothelial and alveolar epithelial type I and type II cells during mouse lung development in the absence of a transgenic reporter. Am J Physiol Lung Cell Mol Physiol. 2020;318(4):L619–30. https://doi.org/10.1152/ajplung.00227.2019.CrossRefPubMed

27.

Major J, Crotta S, Llorian M, McCabe TM, Gad HH, Priestnall SL et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science. 2020;369(6504):712–717. https://doi.org/10.1126/science.abc2061.

28.

Zhang Q, Tian K, Xu J, Zhang H, Li L, Fu Q, et al. Synergistic effects of Cabozantinib and EGFR-Specific CAR-NK-92 cells in renal cell carcinoma. J Immunol Res. 2017;2017:6915912. https://doi.org/10.1155/2017/6915912.CrossRefPubMedPubMedCentral

29.

Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauß A, et al. Cancer Stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol. 2020;11:1280. https://doi.org/10.3389/fimmu.2020.01280.CrossRefPubMedPubMedCentral

30.

Alhabbab RY. Targeting Cancer Stem cells by genetically Engineered Chimeric Antigen Receptor T Cells. Front Genet 20202;11:312. https://doi.org/10.3389/fgene.2020.00312.

31.

Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18(1):153. https://doi.org/10.1186/s12943-019-1090-3.CrossRefPubMedPubMedCentral

32.

Liou GY. CD133 as a regulator of cancer metastasis through the cancer stem cells. Int J Biochem Cell Biol. 2019;106:1–7. https://doi.org/10.1016/j.biocel.2018.10.013.CrossRefPubMed

33.

Asselin-Labat ML, Filby CE. Adult lung stem cells and their contribution to lung tumourigenesis. Open Biol. 2012;2(8):120094. https://doi.org/10.1098/rsob.120094.CrossRefPubMedPubMedCentral

34.

Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringnér M, et al. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer. 2011;11:418. https://doi.org/10.1186/1471-2407-11-418.CrossRefPubMedPubMedCentral

35.

Hiraga T, Nakamura H. Comparable roles of CD44v8-10 and CD44s in the development of bone metastases in a mouse model. Oncol Lett. 2016;12(4):2962–69. https://doi.org/10.3892/ol.2016.4985.CrossRefPubMedPubMedCentral

36.

Mukhopadhyay A, Berrett KC, Kc U, Clair PM, Pop SM, Carr SR, et al. Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. Cell Rep. 2014;8(1):40–9. https://doi.org/10.1016/j.celrep.2014.05.036.CrossRefPubMedPubMedCentral

37.

Shien K, Papadimitrakopoulou VA, Wistuba II. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer. 2016;99:79–87. https://doi.org/10.1016/j.lungcan.2016.06.016.CrossRefPubMed

38.

Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 expression in Lung Cancer. J Thorac Oncol. 2016;11(7):964–75. https://doi.org/10.1016/j.jtho.2016.04.014.CrossRefPubMedPubMedCentral

39.

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16. https://doi.org/10.1016/j.gene.2005.10.018.CrossRefPubMed

40.

Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–54. https://doi.org/10.1038/nrc1609.CrossRefPubMed

41.

Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A. 1992;89(7):2965–9. https://doi.org/10.1073/pnas.89.7.2965.CrossRefPubMedPubMedCentral

42.

Novak D, Hüser L, Elton JJ, Umansky V, Altevogt P, Utikal J. SOX2 in development and cancer biology. Semin Cancer Biol. 2020;67(Pt 1):74–82. https://doi.org/10.1016/j.semcancer.2019.08.007.CrossRefPubMed

43.

Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009;16(12):3488–98. https://doi.org/10.1245/s10434-009-0617-z.CrossRefPubMed

44.

Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, Maier S, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol. 2011;24(7):944–53. https://doi.org/10.1038/modpathol.2011.49.CrossRefPubMed

45.

Donnenberg AD, Hicks JB, Wigler M, Donnenberg VS. The cancer stem cell: cell type or cell state? Cytometry A 201383(1):5–7. https://doi.org/10.1002/cyto.a.22208.

46.

Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol. 2010;34(8):1193–8. https://doi.org/10.1097/PAS.0b013e3181e5e024.CrossRefPubMedPubMedCentral

47.

Kravtsov DS, Erbe AK, Sondel PM, Rakhmilevich AL. Roles of CD4 + T cells as mediators of antitumor immunity. Front Immunol. 2022;13:972021. https://doi.org/10.3389/fimmu.2022.972021.CrossRefPubMedPubMedCentral

48.

Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, et al. MEK inhibition reprograms CD8 + T lymphocytes into memory stem cells with potent antitumor effects. Nat Immunol. 2021;22(1):53–66. https://doi.org/10.1038/s41590-020-00818-9.CrossRefPubMed

49.

Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10. https://doi.org/10.1186/s12943-018-0928-4.CrossRefPubMedPubMedCentral

50.

Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S. CD8 + T cell exhaustion in Cancer. Front Immunol. 2021;12:715234. https://doi.org/10.3389/fimmu.2021.715234.CrossRefPubMedPubMedCentral

51.

Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8(2):2171–86. https://doi.org/10.18632/oncotarget.13895.CrossRefPubMed

52.

Hu Z, Zou D, Fu X, Zhou W. Effect of fine nursing with dietary intervention on pain level of patients with advanced lung cancer. Am J Transl Res. 2023;15(4):2738–46.PubMedPubMedCentral

53.

Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4 + T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2021;28(1–2):5–17. https://doi.org/10.1038/s41417-020-0183-x.CrossRefPubMed

Title: Effects of reprogrammed splenic CD8+ T-cells in vitro and in mice with spontaneous metastatic Lewis lung carcinoma
Authors: E. Skurikhin
N. Ermakova
M. Zhukova
E. Pan
D. Widera
L. Sandrikina
L. Kogai
O. Pershina
A. Pakhomova
V. Yu. Pan
N. Kushlinskii
A. Kubatiev
S. Morozov
A. Dygai
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Metastasis
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-12203-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Chemotherapy-related adverse effects with anthracycline and taxane-containing regimens in patients with localized Breast cancer: a descriptive study

Long noncoding RNA TMPO-AS1 accelerates glycolysis by regulating the miR-1270/PKM2 axis in colorectal cancer

Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: a meta-analysis

Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201)

Clinical analysis of 314 patients with high-grade squamous intraepithelial lesion who underwent total hysterectomy directly: a multi-center, retrospective cohort study

Ovarian cancer cells regulate their mitochondrial content and high mitochondrial content is associated with a poor prognosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer